EP0533408B1 - Kosmetika und Pharmazeutika enthaltend Extensin - Google Patents

Kosmetika und Pharmazeutika enthaltend Extensin Download PDF

Info

Publication number
EP0533408B1
EP0533408B1 EP92308279A EP92308279A EP0533408B1 EP 0533408 B1 EP0533408 B1 EP 0533408B1 EP 92308279 A EP92308279 A EP 92308279A EP 92308279 A EP92308279 A EP 92308279A EP 0533408 B1 EP0533408 B1 EP 0533408B1
Authority
EP
European Patent Office
Prior art keywords
extensin
composition
protein
skin
soluble precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP92308279A
Other languages
English (en)
French (fr)
Other versions
EP0533408A2 (de
EP0533408B2 (de
EP0533408A3 (en
Inventor
Barbara Wolf
Marlene Tietjen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revlon Consumer Products LLC
Original Assignee
Revlon Consumer Products LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25062628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0533408(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revlon Consumer Products LLC filed Critical Revlon Consumer Products LLC
Publication of EP0533408A2 publication Critical patent/EP0533408A2/de
Publication of EP0533408A3 publication Critical patent/EP0533408A3/en
Application granted granted Critical
Publication of EP0533408B1 publication Critical patent/EP0533408B1/de
Publication of EP0533408B2 publication Critical patent/EP0533408B2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q13/00—Formulations or additives for perfume preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/002—Aftershave preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A61Q3/02—Nail coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners

Definitions

  • the invention is in the field of cosmetic and pharmaceutical compositions containing extensin proteins.
  • animal collagen is known to have moisturizing and film forming properties, and is a popular additive to treatment cosmetics.
  • Animal collagen protein is the main component of connective tissues, skin, muscles and tendons. It is a fibrous protein of about 100,000 molecular weight, rich in proline and hydroxyproline, and structurally analogous to a three-stranded rope in which each strand is a polypeptide chain. Collagen is responsible for most of skin structure. In the course of aging the polypeptide chains of collagen polymerize. The result is "cross linking", which causes wrinkling of the skin as well as reduction in skin elasticity.
  • non-collagen animal proteins such as plasma proteins, placental proteins, or proteins from milk sources are also popular as cosmetics additives, as well as proteins from lower animals such as silkworm, fish, bacteria, yeast, or non-specified marine sources.
  • Extensins are a family of plant derived hydroxyproline rich glycoproteins (HRGP) firmly bound to the primary cell wall of several species of monocotyledonous and dicotyledenous plants. Extensins are also rich in serine, valine, tyrosine, lysine, and in some instances threonine, and the polypeptide ' backbone comprises repeating hydroxyproline units in conjunction with other basic amino acids such as valine, lysine, proline, tyrosine, histidine, serine, and threonine. The hydroxyproline component is heavily glycosylated. Extensins play a role in growth, regulation, stress response, cell-cell recognition, and reproductive physiology of plants.
  • HRGP plant derived hydroxyproline rich glycoproteins
  • the protein is widely distributed throughout the plant kingdom. Extensins are generally insoluble in muro because of their extensive cross linking, so the intact protein has not been isolated from mature plants, which has made the scientific study of intact extensin protein much more difficult.
  • a hydrolyzed form of extensin is available commercially through Centerchem, Stamford, Connecticut. However, this hydrolyzed product contains very small polypeptide chains having molecular weights of 100-1500 daltons. The estimated size of intact extensin protein is greater than 100,000 daltons, or about 100,000-150,000 daltons.
  • this soluble form of extensin may be incorporated into cosmetics as an analog for animal collagen and will act to smooth, tighten, and enhance skin texture.
  • Extensins also contain large amounts of humectant sugars which are capable of binding water, thus making them ideal humectants.
  • the invention is directed to cosmetic compositions comprising cosmetically effective film-forming concentrations of a soluble precursor-form extensin protein.
  • the invention is directed to pharmaceutical compositions comprising pharmaceutically effective film-forming concentrations of a soluble precursor-form extensin protein.
  • the invention is directed to the use of a soluble precursor-form of extensin protein in the manufacture of a cosmetic or pharmaceutical composition for applying to the skin as a method of moisturizing and forming a film on skin.
  • Figure 1 shows a scanning electron micrograph of a silicone replica of skin at 25X magnification. About 40 microliters of a 0.2% solution of extensin from carrots was applied to the right half of an area 15 millimeters in diameter (about 44 square millimeters). The left half of the area was left untreated.
  • Figure 2 shows a scanning electron micrograph of a silicone replica of skin at 25X magnification. About 40 microliters of a 0.2% solution of a high molecular weight non-extensin protein from wheat was applied to the right half of an area 15 millimeters in diameter (44 square millimeters of treated surface area), while the left half was left untreated. A comparison of both figures reveals that skin treated with extensin protein has an appreciably more intact and visible film than skin treated with high molecular weight non-extensin wheat protein or untreated skin.
  • extendensin or "extensin protein” means a soluble hydroxyproline-rich glycoprotein analogue to animal collagen which is extracted from plant cell walls.
  • extensins are comprised of a polypeptide backbone comprising repeating hydroxyproline units in conjunction with other basic amino acids such as valine, lysine, proline, tyrosine, histidine, serine, and threonine.
  • extendensin includes extensin hydrolysates wherein the molecular weight of the fragments is from 100 - 100,000 daltons, or more likely 100-1500 daltons; and includes the intact extensin protein which has a molecular weight of about 100,000 daltons up to 150,000 daltons.
  • the extensin hydrolysates may be purchased from Centerchem, Stamford Connecticut, and exhibit molecular weights of 100-1500 daltons.
  • soluble extensin precursors may be extracted from plant species in the growth phase by salt extraction of crude extensin protein fractions from concentrated plant cell suspension pellets or explant homogenates.
  • Various metallic salt solutions are suitable for this purpose including aluminum chloride, calcium chloride, lapyrium chloride, sodium chloride, etc.
  • the crude extensin protein extracts may then be further purified by acid precipitation of contaminants using acids such as trichloroacetic acid. Extensin proteins are generally soluble in 5-10% trichloroacetic acid. Then standard protein purification methods may be used for further purification, for example size exclusion affinity chromatography or ion exchange chromatography.
  • the intact extensin protein (of greater than about 100,000 daltons molecular weight) in the cosmetics of the invention, although the use of extensin hydrolysates of small molecular weight fragments of 100-1500 daltons is suitable also.
  • a 0.5% solution of extensin generally produces a flexible film that keeps the skin pliable and firm for five to six hours.
  • the cosmetic benefits are seen in cosmetic and pharmaceutical compositions as outlined below.
  • the extensin extracts may be incorporated into a variety of cosmetic and pharmaceutical compositions.
  • Cosmetic or pharmaceutical compositions containing effective amounts of extensins improve texture, smoothness, and moisture content of the skin.
  • cosmetic composition means a composition applied externally to skin, nails, or hair of the human body, for purposes of beautifying, colouring, conditioning, or protecting the bodily surface.
  • cosmetic compositions in accordance with the invention include lotions, creams, moisturizers, gels, sun screens, makeup, cleansers, shampoos, hair conditioners, skin firming compositions, protein concentrates, after shaves, eyeshadows, blushes and nail enamels.
  • composition means a composition applied externally to the skin, hair, or nails of the human body for therapeutic purposes.
  • pharmaceutical compositions in accordance with the invention include ointments, creams, lotions, gels and solutions.
  • the invention comprises cosmetic compositions comprising a cosmetically effective amount of extensin protein.
  • a cosmetically effective amount of extensin protein in accordance with the invention is 0.01-30% by weight of the total composition, with 0.1-10% preferred, and 0.5-5% most preferred.
  • the extensin proteins may be incorporated into a wide variety of cosmetic compositions.
  • cosmetically effective amounts of extensin may be incorporated into moisturizing lotions for application to human facial or body skin. These lotions generally contain from about 20-80% oil and 10-80% water in an emulsion form.
  • the moisturizing lotion may contain humectants, emollients, surfactants, fragrances and preservatives. About 5-10% humectant, about 5-20% emollient, and about 0.5-10% surfactant are suggested.
  • Creams generally contain from about 20-70% water and about 30-70% oil.
  • creams may contain a variety of humectants, emollients, surfactants, preservatives, and fragrances. About 5-10% humectant, about 5-20% emollient, and about 0.5-10% surfactant are suggested.
  • Extensins may also be incorporated into treatment makeups.
  • makeup formulations comprising 5-70% oil, 10-95% water, and about 5-40% pigment are suitable.
  • the makeup may contain surfactants, silicone, humectants, emollients, preservatives, fragrances, etc.
  • surfactants silicone, humectants, emollients, preservatives, fragrances, etc.
  • 0.5-10% surfactant, 0.1-30% silicone, 5-10% humectant, 0.1-30% emollient, and 0.1-5% preservative is suggested.
  • Extensins may also be incorporated into colored cosmetics such as eyeshadow or blush.
  • a suitable eyeshadow comprises 5-40% pigments, 1-50% oil, and 1-20% waxes.
  • the composition may contain one or more of 10-60% water, 0.5-30% surfactant, 1-10% humectants, 0.1-5% preservative, and 0.1-20% silicone.
  • Extensins are also suitable for incorporation into shampoos and hair conditioners.
  • Suitable shampoo formulations include 1-40% surfactant and 10-90% water.
  • Suitable hair conditioning formulations include 30-95% water, 0.5-30% conditioning ingredients such as emollients, proteins, shine enhancers, and so forth, and 1-40% surfactant.
  • Hair conditioners and shampoos may also contain thickeners and silicone. About 0.05-15% silicone is suggested in shampoos and hair conditioners.
  • Extensins may also be incorporated into cleansers, aftershaves, toners, fragrance splashes, and even nail treatment products or nail enamels.
  • fragrance splashes, aftershaves and toners generally comprise about 10-70% alcohol.
  • 0.01-5% surfactant may be added as well as 1-5% humectants, and up to 25% perfume.
  • Extensins may be incorporated into traditional nail enamels or nail treatment products which generally comprise about 1-40% film former, 10-50% resin, and 10-70% solvent, in addition to the usual plasticizers, pigments, and wetting agents.
  • the invention is also directed to pharmaceutical compositions comprising pharmaceutically effective amounts of extensin protein.
  • a pharmaceutically effective amount in accordance with the invention means about 0.01-30% of extensin protein, with 0.1-10% preferred, and 0.5-5% most preferred.
  • the extensin proteins may be incorporated into suitable pharmaceutical vehicles such as lotions, creams, ointments, gels, or solutions.
  • suitable ointments are hydrophilic ointments (USP) or petrolatum and cosmetically effective amounts of extensin, protein are incorporated into the ointment for topical application to skin.
  • Suitable lotions and creams are are as mentioned previously for cosmetic compositions. Solutions are made by mixing solutions of extensin protein in deionized water for application to human skin. Gels are made by mixing 1-90% water with a suitable polymer.
  • Suitable humectants for use in the cosmetic compositions of the invention include glycerin, propylene glycol, butylene glycol, urea, sorbitol, sodium PCA, gelatin, polyethylene glycols, sodium lactate, hyaluronic acid, and so on.
  • Suitable emollients include glyceryl stearate, cetyl alcohol, stearyl alcohol, isopropyl stearate, stearyl alcohol, stearyl stearate, isopropyl stearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, sebacates, myristates, palmitates, squalenes, glyceryl monooleate, oleic acids, lanolin, acetylated lanolin alcohols, petrolatum, mineral oils, palmitic acids, isostearyl neopentanoate, etc.
  • amphoteric, anionic, cationic or nonionic surfactants include amphoteric, anionic, cationic or nonionic surfactants.
  • Suitable amphoteric surfactants include imidazolines, betaines, and amino acid salts.
  • Suitable anionic surfactants include fatty acid soaps, salts of higher alkyl sulfates, n-acyl sarcosinates, salts of phosphates, sulfosuccinate salts, alkyl benzene sulfonates, salts of N-acyl glutamate, polyoxyethylene alkyl ether carboxylic acids, and so on.
  • Cationic surfactants include alkyl trimethyl ammonium salts, alkyl pyridinium salts, alkyl quaternary ammonium salts, polyamine fatty acid derivatives, etc.
  • Nonionic surfactants include lipophilics such as sorbitan fatty acid esters, glycerol fatty acids, propylene glycol fatty acid esters; hydrophilics such as polyoxyethylene sorbitan fatty acid esters, polyoxyethylene glycerol fatty acid esters, polyoxyethylene fatty acid esters, polyoxyethylene alkyl ethers, pluronics, polyoxyethylene alkyl phenyl ethers, polyoxyethylene propylene glycol fatty acid esters, and so on.
  • Suitable pigments include organic and inorganic pigments such as talc, mica, titanium dioxide, titanated mica, iron oxides, ultramarines, chromium oxides, carmine, D&C and FD&C colors and lakes, ferric and ferrous oxides, and so on.
  • Suitable preservatives include imidazolidinyl urea, the parabens, quaternium 15, benzyl alcohol, phenoxyethanol and so on.
  • Suitable waxes include beeswax, carnauba, ceresin, microcrystalline, lanolin, paraffin, ozokerite, lanolin alcohol, acetylated lanolin, candelilla, cetyl alcohol, cocoa butter, petrolatum, hydrogenated castor oil spermaceti, bran wax, capok wax, bayberry, etc.
  • the invention is also directed to a method for moisturizing and forming a film on human skin, nails, or hair comprising applying to the surface an effective amount of extensin protein.
  • An effective amount of extensin is about 0.01-30% by weight.
  • the extensin protein may be applied directly to the surface in a solution form, or it may be incorporated into the cosmetic or pharmaceutical compositions mentioned herein.
  • the extensin protein or protein containing composition may be applied to the surface once or twice a day or as necessary. For example, if the extensin protein is incorporated into a facial moisturizer, usually one to two applications of moisturizer per day will provide a beneficial effect. If the extensin proteins are incorporated into shampoos or hair conditioners, usually application once a day or every other day will be sufficient to provide a beneficial effect.
  • Bean seeds (Phaseolus Vulgaris) or carrots (Daucus carota) are purchased from local gardening stores and the seeds germinated on moist filter paper in the dark. Germinated seeds are then planted in large window boxes or in gardens. Young plants are grown and then the hypocotyl and roots harvested and homogenized in 50 mM potassium phosphate buffer pH 6, 1 mM dithiothreitol (DTT), 0.1 mM phenyl methylsulfonyl fluoride and 2 mM ascorbate in an Osterizer (Waring) blender. The homogenate was diluted with 10 mM calcium chloride and centrifuged at 1000 x G. Pellets were extracted again in 100 mM calcium chloride and recentrifuged. The supernatants were combined and dialyzed to remove excess salt. The result was a crude extensin extract suitable for incorporation into cosmetics or pharmaceuticals.
  • Small tomato plants are obtained from local gardening stores and acclimated to outdoor gardens. After two weeks small amounts of plant tissue are cut off and frozen in liquid nitrogen until a sufficient amount is collected (approximately 100 grams of wet tissue). Crude homogenates are made and extracted with 75 mM aluminum chloride.
  • Small pieces of potato are rooted by exposing the pieces to water containing 35 mM sodium azide, 0.5% ferulic acid, 0.05% curcumin, 0.1% carnosine, or 0.05% extract from spinach, gingo bilboa, or ginseng.
  • the root systems formed are harvested and homogenized in 50-100 mM calcium chloride or 150 mM sodium chloride.
  • Pea seeds (Pisum sativum) are germinated and the epicotyl and root sections were dissected and extracted in a loosely stoppered flask at 70° C. with 0.12% v/v acetic acid and 0.3% sodium chlorite for 30 minutes under a nitrogen blanket. After cooling the solution was filtered through coarse glass wool and the residue washed five times with distilled water. Nitrogen is bubbled through the filtrate to remove any extraneous chlorine dioxide. The resulting homogenate is dialyzed to yield a crude extensin protein preparation.
  • An extensin containing oil in water moisturizing lotion is made as follows: w/w% Glyceryl stearate 3.0 PPG-10 lanolin ether 0.5 Mineral oil 6.3 Lanolin alcohol 0.7 Oleic acid 2.7 Isocetyl stearate 10.0 Triethanolamine 1.3 Carbomer 941 0.1 Glycerin 4.0 Preservative 0.4 Extensin solution from carrots 1 5.0 Hydrolyzed extensin polypeptides 2 5.0 Water qs 100.00 1 5% solution 2 5% peptide solids, "Vegagen", Centerchem, Inc., Stamford, CT
  • An oil in water moisturizing cream was made as follows: w/w% Glyceryl stearate 5.0 Cetyl alcohol 2.0 Stearyl alcohol 2.0 Isopropyl stearate 4.0 Mineral oil 12.0 Polysorbate 60 1.0 Glycerin 8.0 Xanthan gum 0.25 Preservative 0.6 Extensin solution from carrots 1 5.0 Hydrolyzed extensin polypeptides from carrots 2 5.0 Water qs 100.00 1 5% solution 2 Veodor, Centerchem, Inc., Stamford, CT
  • An oil/water cream makeup was made as follows: w/w% Octyldodecyl stearyl stearate 4.0 Isocetylstearate 1.0 Glyceryl stearate 6.0 Isostearic acid 2.0 Stearic acid 1.0 Ceteth 10 1.0 Cyclomethicone 12.0 Stearyl alcohol 1.5 Nonionic surfactant mixture 1 1.0 Binders and thickeners 1.7 Titanium dioxide 8.0 Iron oxide 2.0 Propylene glycol 3.0 Triethanolamine 1.5 Preservatives 0.55 Extensin solution from tomato 2 1.0 Water qs 100.00 1 lecithin, polysorbate 20, sorbitanlaurate 2 1.5% solution
  • a water/oil pigment emulsion makeup was made as follows: w/w% Cyclomethicone 22.6 12.0 Dimethicone ---- 5.0 Surfactant 16.0 20.0 Laureth 7 0.5 ---- Laureth 9 ---- ---- Bentone gellant 5.0 ---- Iron oxides 3.1 2.4 Titanium dioxide 12.0 8.5 Talc 4.5 3.3 Sodium chloride 2.0 2.0 Propylene glycol 6.0 8.0 Preservative 0.5 0.5 Extensin solution from potato 0.5 0.5 Water qs 100.0
  • a water/oil pigment emulsion eyeshadow was made as follows: w/w% Cyclomethicone 2.0 Dimethicone 5.0 Surfactant 20.0 Peg-7 C 12-15 ether 0.5 Chromium oxide 6.2 Ultramarine blue 4.0 Titanium dioxide coated mica 6.0 Sodium chloride 2.0 Propylene glycol 8.0 Preservatives 0.3 Extensin solution from potato 1 0.5 Water qs 100.0 1 1% solution
  • a protein shampoo was made as follows: w/w% Ammonium lauryl sulfate 10.0 Cocamide diethanolamine 4.0 Cocamidopropyl betaine 4.0 Ammonium chloride 0.8 Citric acid 0.1 Extensin solution from corn (1%) 1.0 water qs 100.0
  • a creme rinse hair conditioner was made as follows: w/w% Stearalkonium chloride 2.0 Cetyl alcohol 1.0 Stearyl alcohol 0.5 Ceteareth 20 2.0 Xanthan gum 0.5 Citric acid 0.3 Dimethicone 0.2 Extensin solution from corn (1%) 0.2 Water qs 100.0
  • a variety of extensin containing personal care products are made as follows: A B C D w/w% Mineral oil 20.0 ---- ---- ---- Beeswax 2.0 ---- ---- ---- Polysorbate 40 8.0 ---- ---- ---- Polysorbate 20 ---- ---- 1.0 ---- PEG 20 sorbitan beeswax 2.0 ---- ---- ---- Stearic acid 10.0 ---- ---- ---- ---- Petrolatum 4.0 ---- ---- ---- Sorbitol 5.0 ---- ---- ---- Ethyl alcohol ---- 50.0 50.0 50.0 Menthol ---- 0.05 ---- 0.1 Carbomer 940 ---- 0.75 ---- ---- Triethanolamine ---- 0.75 ---- ---- Polysorbate 80/acetyllated lanolin alcohol/cetyl acetate ---- 3.0 ---- ---- Citric acid ---- ----

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (11)

  1. Mittel zur kosmetischen und/oder pharmazeutischen Verwendung auf der Haut, den Nägeln oder dem Haar, in dem der kosmetisch und/oder pharmazeutisch wirksame Bestandteil ein lösliches Vorläuferform-Extensinprotein mit oder ohne Extensinhydrolysat(en) in einer zur Filmbildung wirksamen Konzentration enthält oder daraus besteht.
  2. Mittel nach Anspruch 1, in dem das Molekulargewicht des Extensinhydrolysats (der Extensinhydrolysate), wenn vorhanden, im Bereich von 100 bis 1.500 Dalton liegt.
  3. Mittel nach Anspruch 1 oder 2, in dem der einzige wirksame Bestandteil vom Extensintyp das lösliche Vorläuferform-Extensinprotein ist.
  4. Mittel nach einem der vorstehenden Ansprüche, in dem das lösliche Vorläuferform-Extensinprotein intaktes Extensin (intakte Extensine) mit einem Molekulargewicht von zumindest 100.000 Dalton ist.
  5. Mittel nach Anspruch 4, in dem das Molekulargewicht des intakten Extensins (der intakten Extensine) im Bereich von 100.000 bis 150.000 Dalton liegt.
  6. Mittel nach einem der vorstehenden Ansprüche, in dem die Konzentration des löslichen Vorläuferform-Extensinproteins im Bereich von 0,01 bis 30 Gew.-% liegt.
  7. Mittel nach einem der vorstehenden Ansprüche, in dem die Konzentration des löslichen Vorläuferform-Extensinproteins im Bereich von 0,1 bis 10 Gew.-% liegt.
  8. Mittel nach einem der vorstehenden Ansprüche, in dem die Konzentration des löslichen Vorläuferform-Extensinproteins im Bereich von 0,5 bis 5 Gew.-% liegt.
  9. Kosmetisches Mittel nach einem der vorstehenden Ansprüche, in dem der Rest des Mittels als Creme, Lotion, Gel, Toner, Duftwasser (fragrance splash), Makeup, Rouge, Lidschatten, Nagelpflegemittel, Aftershave, Reiniger, Shampoo oder Haarweichspüler formuliert ist.
  10. Arzneimittel nach einem der Ansprüche 1 bis 8, in dem der Rest des Mittels als Lotion, Creme, Salbe, Gel oder Lösung formuliert ist.
  11. Verwendung eines löslichen Vorläuferform-Extensinproteins mit oder ohne Extensinhydrolysat(en) zur Herstellung eines Arzneimittels zur therapeutischen Behandlung von Haut, Nägeln oder Haar.
EP92308279A 1991-09-18 1992-09-11 Kosmetika und Pharmazeutika enthaltend Extensin Expired - Lifetime EP0533408B2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76157491A 1991-09-18 1991-09-18
US761574 1991-09-18

Publications (4)

Publication Number Publication Date
EP0533408A2 EP0533408A2 (de) 1993-03-24
EP0533408A3 EP0533408A3 (en) 1993-04-14
EP0533408B1 true EP0533408B1 (de) 1996-12-27
EP0533408B2 EP0533408B2 (de) 2001-02-28

Family

ID=25062628

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92308279A Expired - Lifetime EP0533408B2 (de) 1991-09-18 1992-09-11 Kosmetika und Pharmazeutika enthaltend Extensin

Country Status (9)

Country Link
EP (1) EP0533408B2 (de)
JP (1) JPH06107517A (de)
AT (1) ATE146673T1 (de)
CA (1) CA2077991C (de)
DE (1) DE69216188T3 (de)
DK (1) DK0533408T3 (de)
ES (1) ES2096727T5 (de)
GR (1) GR3022941T3 (de)
ZA (1) ZA927075B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709810B2 (en) 2011-07-22 2014-04-29 I.R.B. Istituto di Ricerche Biotechnologiche S.R.L. Preparation and use of meristematic cells belonging to the Dendrobium phalaenopsis, Ansellia, Polyrrhiza, Vanilla, Cattleya and Vanda genera with high content of phenylpropanoids, hydrosoluble polysaccharides and extensins

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449519C1 (en) * 1994-08-09 2001-05-01 Revlon Consumer Prod Corp Cosmetic compositions having keratolytic and anti-acne activity
IT1271342B (it) * 1994-12-28 1997-05-27 Indena Spa Proteine ricche in idrossiprolina e formulazioni farmaceutiche e cosmetiche che le contengono
FR2751533B1 (fr) 1996-07-23 2003-08-15 Oreal Composition de teinture d'oxydation pour fibres keratiniques comprenant un polymere amphiphile non-ionique
FR2753093B1 (fr) * 1996-09-06 1998-10-16 Oreal Composition de teinture d'oxydation pour fibres keratiniques comprenant un polymere amphiphile anionique
FR2753094B1 (fr) * 1996-09-06 1998-10-16 Oreal Composition de teinture d'oxydation pour fibres keratiniques comprenant un polymere amphiphile anionique
GB2336156B (en) * 1998-04-09 2003-05-07 Mars Uk Ltd Adhesives
KR100784486B1 (ko) * 2007-01-08 2007-12-11 주식회사 에스티씨나라 피부 타이트닝용 화장료 조성물 및 이를 이용한 피부타이트닝 방법
JP2008195651A (ja) * 2007-02-13 2008-08-28 Noevir Co Ltd 保湿剤
CN102008401A (zh) * 2010-11-22 2011-04-13 马南行 一种放松面部肌肉的生物制剂及其制造方法
EP3817715B1 (de) 2018-07-06 2023-05-17 Laboratoires de Biologie Végétale Yves Rocher Kosmetische verwendung von hrgp (hydroxyprolinreichen glykoproteinen) aus ajuga-reptans-zellen zur vorbeugung und/oder bekämpfung der auswirkungen der hautalterung
IT201800006983A1 (it) * 2018-07-06 2020-01-06 Metodo di estrazione di glicoproteine ricche di idrossiprolina monomeriche ed estratto ottenuto con questo metodo

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709810B2 (en) 2011-07-22 2014-04-29 I.R.B. Istituto di Ricerche Biotechnologiche S.R.L. Preparation and use of meristematic cells belonging to the Dendrobium phalaenopsis, Ansellia, Polyrrhiza, Vanilla, Cattleya and Vanda genera with high content of phenylpropanoids, hydrosoluble polysaccharides and extensins

Also Published As

Publication number Publication date
DE69216188T3 (de) 2001-09-20
EP0533408A2 (de) 1993-03-24
EP0533408B2 (de) 2001-02-28
ZA927075B (en) 1994-03-16
CA2077991C (en) 1997-02-25
GR3022941T3 (en) 1997-06-30
JPH06107517A (ja) 1994-04-19
ES2096727T3 (es) 1997-03-16
DE69216188D1 (de) 1997-02-06
DE69216188T2 (de) 1997-06-05
ES2096727T5 (es) 2001-07-01
DK0533408T3 (da) 1997-07-07
CA2077991A1 (en) 1993-03-19
ATE146673T1 (de) 1997-01-15
EP0533408A3 (en) 1993-04-14

Similar Documents

Publication Publication Date Title
US4839164A (en) Trehalose containing cosmetic composition and method of using it
US5443855A (en) Cosmetics and pharmaceuticals containing extensins and related methods
CN1893911B (zh) 含有四肽和三肽混合物的配方
US7241871B2 (en) Method and process for the production of collagen preparations from invertebrate marine animals and compositions thereof
US5449519A (en) Cosmetic compositions having keratolytic and anti-acne activity
US20050063932A1 (en) Skin care compositions including hexapeptide complexes and methods of their manufacture
EP0533408B1 (de) Kosmetika und Pharmazeutika enthaltend Extensin
US20150126759A1 (en) Hydroxytyrosol derivatives, their method of preparation and use in personal care
US6649177B2 (en) Formulations including hydrolyzed jojoba protein
KR960000855A (ko) L-카르니틴염과 이를 함유한 피부질환 치료용 화장품 조성물 및 약제조성물
US4760095A (en) Moisturizers
US6552171B2 (en) Hydrolyzed jojoba protein
JP3513872B2 (ja) 皮膚外用剤
US20050008666A1 (en) Extracts of nonfruiting nonphotosynthetic filamentous bacteria for strengthening keratin materials
JPH0532533A (ja) 化粧料
JPH0543442A (ja) 皮膚化粧料
JP3278138B2 (ja) 皮膚外用剤
JPH03112912A (ja) 化粧料組成物
JPH0429912A (ja) 新規化粧料
JP2002145719A (ja) 化粧料
US7608250B2 (en) Cosmetic composition
JPS59219227A (ja) 「ざ」瘡治療用組成物
JP2780805B2 (ja) 新規な皮膚外用剤組成物
KR102793054B1 (ko) Chromis 속 어류의 가수분해물 제조방법 및 황색포도상구균에 효과가 있는 항균, 항산화 활성 펩타이드 분리 방법
GB2105727A (en) Allantoin amino acid compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RTI1 Title (correction)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: REVLON CONSUMER PRODUCTS CORPORATION

K1C1 Correction of patent application (title page) published

Effective date: 19930324

17P Request for examination filed

Effective date: 19930929

17Q First examination report despatched

Effective date: 19941118

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19961227

REF Corresponds to:

Ref document number: 146673

Country of ref document: AT

Date of ref document: 19970115

Kind code of ref document: T

REF Corresponds to:

Ref document number: 69216188

Country of ref document: DE

Date of ref document: 19970206

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: 71230

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVATOR AG

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2096727

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19970217

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3022941

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBQ Unpublished change to opponent data

Free format text: ORIGINAL CODE: EPIDOS OPPO

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

26 Opposition filed

Opponent name: REVLON CONSUMER PRODUCTS CORPORATION

Effective date: 19970926

R26 Opposition filed (corrected)

Opponent name: INDENA S.P.A.

Effective date: 19970926

NLR1 Nl: opposition has been filed with the epo

Opponent name: REVLON CONSUMER PRODUCTS CORPORATION

NLR1 Nl: opposition has been filed with the epo

Opponent name: INDENA S.P.A.

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLBF Reply of patent proprietor to notice(s) of opposition

Free format text: ORIGINAL CODE: EPIDOS OBSO

PLAW Interlocutory decision in opposition

Free format text: ORIGINAL CODE: EPIDOS IDOP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20000808

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20000809

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20000811

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20000825

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20000828

Year of fee payment: 9

Ref country code: CH

Payment date: 20000828

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20000830

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20000831

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20000907

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20000918

Year of fee payment: 9

PLAW Interlocutory decision in opposition

Free format text: ORIGINAL CODE: EPIDOS IDOP

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20001017

Year of fee payment: 9

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

27A Patent maintained in amended form

Effective date: 20010228

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: CH

Ref legal event code: AEN

Free format text: AUFRECHTERHALTUNG DES PATENTES IN GEAENDERTER FORM

NLR2 Nl: decision of opposition
ITF It: translation for a ep patent filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20010528

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20010531

ET3 Fr: translation filed ** decision concerning opposition
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20010627

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20010627

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Kind code of ref document: T5

Effective date: 20010528

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010911

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010911

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20010927

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010930

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

EUG Se: european patent has lapsed

Ref document number: 92308279.6

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20020829

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20030807

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20030821

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20030825

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050401

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20040911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050531

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050911

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20040913

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20010930